GAPAID
Genes And Proteins for AutoImmunity Diagnostics
| Coordinatore | TOSCANA BIOMARKERS S.R.L
Organization address
address: VIA FIORENTINA 1 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 1˙715˙535 € |
| EC contributo | 1˙210˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2012 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-09-01 - 2014-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TOSCANA BIOMARKERS S.R.L
Organization address
address: VIA FIORENTINA 1 contact info |
IT (SIENA) | coordinator | 181˙015.82 |
| 2 |
PROGENIKA BIOPHARMA SA
Organization address
address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" contact info |
ES (DERIO - VIZCAYA) | participant | 581˙507.61 |
| 3 |
Pharma Quality Europe S.R.L.
Organization address
address: Via Brunetto Degli Innocenti 2 contact info |
IT (Figline Valdarno) | participant | 209˙047.25 |
| 4 |
DIAGNOSTICUM GYARTO ES FORGALMAZO ZARTKORUEN MUKODO RESZVENYTARSASAG
Organization address
address: ATTILA U 126 contact info |
HU (BUDAPEST) | participant | 194˙371.32 |
| 5 |
OMNILAB IBERIA SL
Organization address
address: CALLE RIOS ROSAS 11 ESCALERA A 11 contact info |
ES (MADRID) | participant | 30˙586.00 |
| 6 |
UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
IT (PISA) | participant | 13˙472.00 |
| 7 |
EOTVOS LORAND TUDOMANYEGYETEM
Organization address
address: EGYETEM TER 1-3 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 8 |
PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS
Organization address
address: VASVARI PAL UTCA 4 contact info |
HU (PECS) | participant | 0.00 |
| 9 |
UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA
Organization address
address: BARRIO SARRIENA S N contact info |
ES (LEIOA) | participant | 0.00 |
| 10 |
UNIVERSITA DEGLI STUDI DI FIRENZE
Organization address
address: Piazza San Marco 4 contact info |
IT (Florence) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Rheumatoid arthritis (RA) and sistemic lupus erythematosus (SLE) are two autoimmune diseases that respectively affect an estimated population of 1.537.000 and 1.272.000 of patients in Europe. Such diseases show a long prodrome during which there are no clinical symptoms. In some cases, therapeutic treatments have been developed to improve patients quality of life. Therefore, reliable diagnostic/prognostic tools are necessary not only for an early diagnosis and for monitoring disease activity, but also for setting up personalized therapeutic treatments. The clinical diagnosis of RA and SLE is assisted by the use of in vitro diagnostic tests aimed at the evaluation of the presence/level of few autoantibodies circulating in serum. Yet, this diagnostic approach is unsatisfactory because it can assist the diagnosis only after the first disease onset, it is not useful to evaluate the disease susceptibility for an early prevention, and it does not provide information to follow the disease progression for the set up of personalized therapeutic treatments. To solve these drawbacks, the GAPAID project is aimed at supplying the SME participants of the scientific and technological activities necessary to develop a novel diagnostic / prognostic platform for patients affected by RA and SLE. To this aim the scientific activities will be focused on the discovery of the diagnostic and prognostic value of the genetic and serological profiles associated to RA and SLE. The technological activities will contribute to develop multiplex arrays for the contemporary detection of more analytes and to set up a software for the RA and SLE diagnosis / prognosis by matching the clinical, genetic, and serological data. The exploitation of the scientific and technological results will allow the SME participants to the GAPAID proposal to develop and to further commercialize both for RA and SLE an in vitro diagnostic product composed by a genetic array, a serological array, and a software.'